WHO Priority Pathogens List paper is published; Industry action report to be released

Dear All:

First, the methods behind the WHO Priority Pathogens List (PPL, released on 25 Feb 2017) have now been published by Tacconelli et al. in Lancet Infectious Diseases along with an editorial by Tillottson. As further context while you review these excellent papers, you might also find it helpful to have to hand this slide deck comparing the WHO PPL, the 2013 CDC threat list, and the 2008-9 ESKAPE pathogen list. (11 Feb 2020 addendum: I have updated that deck to also show the CDC 2019 threat list. Get the new deck here, go here for a newsletter about CDC’s update, and go here for a discussion of the problem of setting antibiotic R&D priorities.)

You should read the papers yourself, but the quick summary is that the authors used multicriteria decision analysis across 10 axes (mortality, health-care burden, community burden, prevalence of resistance, 10-year trend of resistance, transmissibility, preventability in the community setting, preventability in the health-care setting, treatability, and pipeline) to prioritize the pathogens. Very importantly, they obtained input from 70 experts spanning all 6 WHO regions, thus ensuring a broad view on global needs.

Second, there has been a lot of action underway to address the gaps identified by the WHO PPL and the related WHO pipeline review from this past summer. I am seeing significant amounts of company-level activity and one measure of this is that CARB-X now lists 22 projects in its portfolio page. As an additional perspective on recent actions at the Industry level, I’ve learned that the AMR Industry Alliance will release its first Global Progress report on 18 Jan 2018 in Geneva. You can register to attend that meeting via this link. This is all very exciting to see!

In closing, all best wishes for the holidays and thank you for being one of the just over 1,000 subscribers to this newsletter! I’ve enjoyed writing these occasional updates and I’ve also appreciated all the helpful comments and tips that I’ve received. 

Ho, ho, ho! –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

Impact of PASTEUR: 9.9m lives saved, ROI of 125:1

Impact of PASTEUR: 9.9m lives saved, ROI of 125:1 Dear All (and with thanks to Kevin Outterson for being lead author on this newsletter), (wonkish alert on this one … refresh your coffee and dig in!) The Center for Global Development have released a blog post and a paper estimating the potential impact of the PASTEUR Act.

Five FDA RFPs! Antifungal animal models, MIC breakpoints, and more!

Dear All, I just today learned that FDA have posted their FY 2023 funding opportunities. All the details are on this webpage and I’m just going to reproduce the text below my signature for your reference. I’ll also add a few details in italics. Lots of good opportunities here! –jr John H. Rex, MD |

WAAW! Must-Read Article, A Quiz, A Video, A Call to Action

Notes: Newsflash … BARDA have opened their long-running BAA-18-100-SOL-00003 to include support for antifungal agents. Search for “antifungal” in the posted .pdf to find the text. The first deadline for proposals is 15 Dec 2022 and further deadlines will doubtless follow: as shown on page 9, this BAA has offered 4 deadlines/year since 2018!  Dear All, In

Fireside Chat with AMR Action Fund CIO Martin Heidecker

Dear All, Ahead of World Antimicrobial Awareness Week, I sat down with AMR Action Fund Chief Investment Officer Martin Heidecker for a Fireside Chat. It was a fabulous conversation that covered everything from how the Fund’s investment process works to what it’s looking for in portfolio companies to broader investment trends in the AMR space.  As

Scroll to Top